论文部分内容阅读
应用核素偶联的单抗进行放射免疫治疗已经被公认为新一代治疗难治非霍奇金淋巴瘤(non-Hodgkin’slymphoma,NHL)的有效手段。90Y-ibritumomab tiuxetan(Zevalin)和131I-tositumomab tiuxetan(Bexxar)等CD20核素标记的单克隆抗体在难治或复发的滤泡型/低度恶性或转化型非霍奇金淋巴瘤的治疗研究中取得显著成效。本文将对Zevalin和Bexxar的作用机制、治疗方法、临床研究及安全性作一个回顾性的总结及展望。
Radionuclide therapy using radionuclide conjugated monoclonal antibodies has been recognized as a new generation of effective therapy for refractory non-Hodgkin’s lymphoma (NHL). CD20 nuclide-labeled monoclonal antibodies such as 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab tiuxetan (Bexxar) have been used in the treatment of refractory or relapsed follicular / low-grade or non-Hodgkin’s lymphoma Achieved remarkable results. This article will provide a retrospective summary and prospect of the mechanism of action, treatment, clinical research and safety of Zevalin and Bexxar.